medical affairs operations, particularly for additional gene therapy product candidates for IRDs. The five primary areas of our pre-launch efforts include patient identification, ensuring market access, developing a high quality delivery and
or analytical methodologies, there is increased risk that FDA or other regulatory authorities may not consider the endpoints of our clinical trials to provide clinically meaningful results and that these results may be difficult to analyze.•We have entered into, and may in the future enter into additional, collaborations with third parties to develop product candidates.
opinion and increased regulatory scrutiny of gene therapy may damage public perception of the safety of our product candidates and adversely affect our ability to conduct clinical trials or obtain regulatory approvals for our product candidates.•We may not be successful in our efforts to identify or discover additional product candidates and may fail to capitalize on programs or product candidates that
Accordingly, the information contained herein may be different than the information you receive from other public companies in which you hold stock.8Table of ContentsThe offeringCommon stock offered by us2,000,000 sharesCommon stock offered by the selling stockholder1,000,000 sharesCommon stock to be outstanding after this offering26,796,961 sharesOption to purchase additional sharesThe underwriters have an option for a period of 30 days from the date of this prospectus to purchase from us and the selling stockholder up to 450,000 additional shares of our common stock.Use of proceedsWe intend to use the net proceeds to us from this offering to fund preclinical and clinical activities for ourSPK-TPP1program; to fund preclinical and clinical activities for ourSPK-FVIIIprogram; to fund other ophthalmic, hematologic and neurodegenerative preclinical programs and to advance product candidates into clinical development; and the remainder for working capital, general and administrative expenses, internal research and
development expenses and other general corporate purposes, including pre-launch activities forSPK-RPE65, capital expenditures, in-licenses and potential acquisitions.We will not receive any proceeds from the sale of any shares by the selling stockholder.See “Use of proceeds” for more information.Risk factorsYou should read the “Risk factors” section of this prospectus for a discussion of factors to consider carefully before deciding to invest in shares of our common stock.NASDAQ Global Select Market symbol“ONCE”The number of shares of our common
successfully complete clinical trials;•continue our clinical development of our product candidates, including our Phase 1/2 clinical trials forSPK-CHMandSPK-FIX;•initiate additional preclinical studies and clinical trials for our other product candidates;•seek to identify additional product candidates;•validate a commercial-scale cGMP manufacturing facility;•further develop our gene therapy platform;•expand our medical affairs capabilities;•establish a sales, marketing and distribution infrastructure to commercialize any product candidates for which we may obtain marketing approval;•maintain, expand and protect our intellectual property portfolio; and•acquire or in-license other product candidates and technologies.To become and remain profitable, we must develop and eventually commercialize product candidates with significant market potential.
services to support clinical development and the market demand for our product candidates, if approved;•obtaining market acceptance of our product candidates as a viable treatment option;•addressing any competing technological and market developments;•implementing additional internal systems and infrastructure, as needed;•negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter and performing our obligations in such collaborations;•maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how;•avoiding and defending against third-party interference or infringement claims; and•attracting, hiring and retaining qualified personnel.Even if one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate.
future capital requirements will depend on many factors, including:•the costs of preparing and filing a BLA with FDA and an MAA with EMA forSPK-RPE65;•the cost and our ability to establish medical, commercial and manufacturing capabilities required to support the launch ofSPK-RPE65;•whether additional clinical testing is required to secure regulatory approvals for all intended or desired indications ofSPK-RPE65;15Table of Contents•the scope, progress, results and costs of drug discovery, recruitment, laboratory testing, preclinical development and clinical trials for our other product
property-related claims;•our current collaboration agreements remaining in effect and our achievement of milestones under those agreements;•our ability to establish and maintain additional collaborations on favorable terms, if at all; and•the extent to which we acquire or in-license other product candidates and technologies.Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes
have contracted to perform certain of those functions;•delays in having subjects complete participation in a trial or return for post-treatment follow-up;•clinical trial sites or subjects dropping out of a trial;•selection of clinical endpoints that require prolonged periods of clinical observation or analysis of the resulting data;•occurrence of serious adverse events associated with the product candidate that are viewed to outweigh its potential benefits;•occurrence of serious adverse events in trials of the same class of agents conducted by other sponsors; or•changes in regulatory requirements and guidance that require amending or submitting new clinical protocols.Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to generate revenues from
described above may inhibit our ability to commercialize our product candidates and adversely affect our business, financial condition, results of operations and prospects.In addition, FDA’s policies, and those of equivalent foreign regulatory agencies, may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our
Sales of our product candidates outside of the United States will be subject to foreign regulatory requirements governing clinical trials and marketing approval.
may not be able to further develop our product candidates and our business, financial condition, results of operations and prospects may be materially and adversely affected.Risks related to manufacturingGene therapies are novel, complex and difficult to manufacture.
availability ofSPK-RPE65could be substantially diminished, which would adversely affect our business, financial condition, results of operations and prospects.Our efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may never be successful.
will be subject to additional risks in commercializing our product candidates outside the United States, including:•different regulatory requirements for approval of drugs and biologics in foreign countries;•reduced protection for intellectual property rights;•unexpected changes in tariffs, trade barriers and regulatory requirements;•economic weakness, including inflation, or political instability in particular foreign economies and markets;•compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;•foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in